In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Meda completes acquisition of Valeant western and eastern European businesses

This article was originally published in Scrip

Executive Summary

Medahas completed its acquisition of Valeant Pharmaceutical's business in western and eastern Europe for $425 million, after certain closing adjustments raised the amount from the previously announced $392 million. The combined revenue of Valeant's products in western and eastern Europe last year was SEK520 million ($86 million; Scrip Online, August 8th, 2008). Through the acquisition, Meda hopes to enter Russia, as well as create significant market synergies with products in its pipeline.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts